Regeneron said a phase three clinical trial of the drug reduced the risk of symptomatic infections in individuals by 81%. Source

JOIN NCOV.LINK NEWSLETTER

And get notified everytime we publish a new Important announcements. We will not email you often, unless there are important things that need to get in touch with you, such as added new tools or new domain names.